Company Encyclopedia
View More
name
TIBET PHARMA
600211.SH
Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds, and other fields.
402.16 B
600211.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking8/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE27.33%A
    • Profit Margin36.07%A
    • Gross Margin90.61%A
  • Growth ScoreC
    • Revenue YoY-7.52%D
    • Net Profit YoY33.05%B
    • Total Assets YoY24.52%A
    • Net Assets YoY7.56%B
  • Cash ScoreD
    • Cash Flow Margin277.27%C
    • OCF YoY-7.52%D
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreB
    • Gearing Ratio32.25%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ruizheng Gene completed a $75 million Series A financing, initiating a comprehensive strategic partnership with TIBET PHARMA and CMS

    On September 30th, Ruizheng Gene Co., Ltd. announced the completion of a Series A financing totaling USD 75 million and initiated a comprehensive strategic cooperation with the Series A investors TIBET PHARMA and CMS

    Zhitong·
    SH
    600211
    -0.43%
    HK
    00867
    +0.60%
    Zhitong·
    SH
    600211
    -0.43%
    HK
    00867
    +0.60%

    Innovative drug concept stocks continue to decline, BrightGene falls over 8%

    Innovative drug concept stocks continue to decline, BrightGene fell over 8%, TIBET PHARMA fell over 7%, Foyou Pharma, Zhendong Pharmaceutical, and Maiwei Biotech all dropped

    Zhitong·
    SH
    601089
    -1.68%
    SH
    688166
    +0.21%
    SH
    600211
    -0.43%
    Zhitong·
    SH
    601089
    -1.68%
    SH
    688166
    +0.21%
    SH
    600211
    -0.43%

    TIBET PHARMA provides a guarantee of 160 million for its subsidiary, with overall risks being controllable

    Tibet Nordicon Pharmaceutical Co., Ltd. provides a guarantee of 160 million yuan for its wholly-owned subsidiary to support its application for comprehensive credit from the bank. The guarantee has completed the approval process, and the current guarantee balance is 378.8029 million yuan, accounting for 18.44% of net assets. The company stated that the creditworthiness and debt repayment ability of the guaranteed party are good, and the overall risk is controllable

    Zhitong·
    SH
    600211
    -0.43%
    Zhitong·
    SH
    600211
    -0.43%

    TIBET PHARMA released its semi-annual performance report, with a net profit attributable to the parent company of 567 million yuan, a year-on-year decrease of 8.96%

    According to the Zhitong Finance APP, TIBET PHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.651 billion yuan, a year-on-year increase of 2.23%; the net profit attributable to shareholders of the listed company was 567 million yuan, a year-on-year decrease of 8.96%; the net profit after deducting non-recurring gains and losses was 543 million yuan, a year-on-year increase of 3.69%; the basic earnings per share were 1.76 yuan. The company plans to distribute a cash dividend of 8.81 yuan (tax included) for every 10 shares to all shareholders

    Zhitong·
    SH
    600211
    -0.43%
    Zhitong·
    SH
    600211
    -0.43%

    TIBET PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 13.95%

    According to the Zhitong Finance APP, TIBET PHARMA disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 712 million yuan, a year-on-year increase of 1.12%; the net profit attributable to the parent company was 269 million yuan, a year-on-year decrease of 13.95%; the net profit excluding non-recurring gains and losses was 253 million yuan, a year-on-year increase of 7.90%. The basic earnings per share were 0.84 yuan

    Zhitong·
    SH
    600211
    -0.43%
    Zhitong·
    SH
    600211
    -0.43%
    © 2025 Longbridge｜Disclaimer